Kazan Pharmaceutical Plant Sever Pharmaceuticals, part of the Izvarino Pharma Group, has started production of active pharmaceutical ingredients (APIs) for cancer drugs. As reported by the press service of Tatarstan’s leadership, Rustam Minnikhanov, in his capacity as an important government official, was involved in the launching ceremony of the production.
In July, Sever received a license from the Ministry of Industry and Trade for the production of highly active pharmaceutical substances by chemical synthesis. Now, the company is launching a full-cycle production of immunosuppressants for patients who have undergone organ transplants, as well as medications for the treatment of cancerous diseases — from the synthesis of APIs to packaging and market release.
The company’s main goals are “import substitution and Russia’s sovereignty in the field of medicines for transplantation and cancer treatment.”
Izvarino Pharma acquired the Sever biological and organic synthesis plant in Kazan in 2023 “in order to ensure a full production cycle and localization of production,” after which it began to modernize the facility. Investments in the project were estimated at 1.1 billion rubles. The Kazan site was intended to produce, among other drugs, Tacrolimus (an immunosuppressant widely used to prevent transplant rejection), Everolimus, Abiraterone Acetate, Lenalidomide and Nilotinib.
